Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [12/05/2025 07:02 PST] EOLS Expected to Trade Up After Bullish Patterns Develop
• [11/25/2025 06:05 PST] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [11/13/2025 12:42 PST] Evolus, Inc. (NASDAQ:EOLS), Up By 100% ($6.56) From $6.56 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/10/2025 07:39 PST] EOLS Expected to Trade Up After Bullish Patterns Develop
• [11/07/2025 06:24 PST] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [10/27/2025 06:49 PDT] EOLS Expected to Trade Up After Bullish Patterns Develop